Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis

American Journal of Hematology

Volumn 72, Issue 2, 2003, Pages 143-146

  Cesaro, Simone ^a   Gazzola, Maria Vittoria ^a   Marson, Piero ^b   Calore, Elisabetta ^a   Caenazzo, Luciana ^c   Destro, Roberta ^a   De Silvestro, Giustina ^b   Varotto, Stefania ^a   Pillon, Marta ^a   Zanesco, Luigi ^a   Messina, Chiara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c Inst of Forensic Medicine of Padova   (Italy)

Author keywords

Fludarabine; Hemophagocytic lymphohistiocytosis; Melphalan; Peripheral allogeneic stem cell transplantation; Thiotepa

Indexed keywords

CD34 ANTIGEN; ETOPOSIDE; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN; THIOTEPA;

ARTICLE; CASE REPORT; CHILDHOOD DISEASE; CHIMERA; CLINICAL FEATURE; CONDITIONING; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HLA MATCHING; HUMAN; INFANT; INFECTION; NEUTROPHIL; PRIORITY JOURNAL; REMISSION; THROMBOCYTE; TREATMENT OUTCOME;

ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; GRAFT SURVIVAL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; INFANT; MELPHALAN; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; THIOTEPA; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 12244267058     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10266     Document Type: Article

References (16)

1. Ohadi M, Lalloz MRA, Sham P, et al. Localization of a gene for hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999;64:165-171.
2. Dufourq-Lagelouse R, Jabado N, Le Deist F, et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Am J Hum Genet 1999;64:172-179.
3. Stepp SE, Dufourq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999;286:1957-1959.
4. Aricò M, Janka G, Fisher A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the international registry. Leukemia 1996;10:197-203.
5. Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Ped Oncol 1997;28:342-347.
6. Baker S, De Laat C, Steinbuch M, et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood 1997:89:3857-3863.
7. Durken M, Finckenstein FG, Jana GE. Bone marrow transplantation in hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2001;41:89-95.
8. Mèresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992;10:135-141.
9. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-3020.
10. Bacigalupo A, Oneto R, Bruno B, et al. Serum cholinesterase is an early and sensitive marker of graft-versus-host disease (GVHD) and transplant-related mortality (TRM). Bone Marrow Transplant 2001;28:1041-1045.
11. Rozman C, Carreras E, Qian C, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplantation for leukemia. Bone Marrow Transplant 1996;17:75-80.
12. Durken M, Horstmann M, Bieling P, et al. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol 1999:106:1052-1058.
13. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998;6:1562-1568.
14. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-1193.
15. Giralt S, Thall PF, Khouri I, et al. Melphalan purine analogue-containing preparative regimes: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
16. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2002;99: 1071-1078.